Abstract
The purpose of this study was to determine, in a model based on Europeans at risk of stroke by virtue of atrial fibrillation (AF), the net clinical benefit of edoxaban in the reduction of the risk of stroke, mortality, and of hemorrhage. Vitamin K antagonists (e.g., warfarin) are commonly underused because of such factors as fear of hemorrhage in patients with high-risk AF. The non-vitamin K antagonist oral anticoagulants are similarly or more effective than warfarin and have lower rates of serious hemorrhage. Although outcomes of the ENGAGE AF-TIMI 48 trial that compared the non-vitamin K antagonist oral anticoagulant edoxaban with warfarin and indicated similar efficacy and better safety compared with warfarin for stroke prevention in AF, the application of trial data to the general population is unknown. This study modelled a treatment effect of edoxaban on the risks of thromboembolism, major bleeding, and death in a real-world population of patients with AF drawn from the Euro Heart Survey, and extrapolated this to the general European population. In those at high risk of stroke (CHA2DS2VASc ≥2), edoxaban would need to be taken by 319 patients to prevent 1 thromboembolism, major bleeding event, or death compared with warfar...Continue Reading
References
Oct 12, 2002·BMJ : British Medical Journal·David A FitzmauriceGregory Y H Lip
Apr 22, 2005·Journal of Thrombosis and Haemostasis : JTH·S SchulmanUNKNOWN Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on T
Oct 6, 2005·European Heart Journal·Robby NieuwlaatUNKNOWN European Heart Survey Investigators
Jan 21, 2006·European Heart Journal·Marjo Hordijk-TrionUNKNOWN EHS-CR Investigators
Feb 24, 2006·International Journal of Clinical Practice·L BoulangerJ Menzin
Aug 29, 2006·European Heart Journal·Simona MonteGianni Tognoni
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Sep 2, 2009·Annals of Internal Medicine·Daniel E SingerAlan S Go
Sep 19, 2009·Chest·Gregory Y H LipHarry J G M Crijns
Mar 20, 2010·Chest·Ron PistersGregory Y H Lip
Sep 30, 2010·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·A John CammUNKNOWN ESC Committee for Practice Guidelines
Oct 23, 2010·Thrombosis and Haemostasis·Neil S RoskellJonathan M Plumb
Oct 30, 2010·Journal of Thrombosis and Haemostasis : JTH·T P Van StaaG Y H Lip
Jun 16, 2011·British Journal of Haematology·David KeelingUNKNOWN British Committee for Standards in Haematology
Jul 27, 2011·Nature Reviews. Cardiology·Gregory Y H Lip
Jul 27, 2011·Thrombosis and Haemostasis·Jonas Bjerring OlesenChristian Torp-Pedersen
Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Aug 30, 2011·The New England Journal of Medicine·Christopher B GrangerUNKNOWN ARISTOTLE Committees and Investigators
Sep 9, 2011·Thrombosis and Haemostasis·A M GallagherT-P van Staa
Dec 14, 2011·Age and Ageing·Roman Romero-Ortuno, Diarmuid O'Shea
Dec 22, 2011·Thrombosis and Haemostasis·Amitava BanerjeeGregory Y H Lip
Nov 28, 2012·Thrombosis and Haemostasis·Ron PistersGregory Y H Lip
Nov 21, 2013·The New England Journal of Medicine·Robert P GiuglianoUNKNOWN ENGAGE AF-TIMI 48 Investigators
Mar 1, 2014·Thrombosis and Haemostasis·Flemming SkjøthGregory Y H Lip
May 27, 2014·The American Journal of Medicine·Pilar GallegoGregory Y H Lip
Jun 24, 2014·PloS One·Paolo VerdecchiaGianpaolo Reboldi
Nov 2, 2014·Circulation·David J GrahamJeffrey A Kelman
Nov 25, 2014·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Peter Brønnum NielsenTorben Bjerregaard Larsen